XM does not provide services to residents of the United States of America.
I
I

Illumina

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Illumina Files For Mixed Shelf

BRIEF-Illumina Files For Mixed Shelf Sept 4 (Reuters) - Illumina Inc ILMN.O : ILLUMINA INC FILES FOR MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING Source text for Eikon: [ID:n0001193125-24-212682] Further company coverage: ILMN.O
I

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Voyager Midstream, Attica Bank and Semnur Pharmaceuticals Sept 3 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 20:00 GMT on Tuesday: ** Voyager Midstream Holdings, a portfolio firm of Pearl Energy Investments, said it has acquired some natural gas gathering and processing assets from Phillips 66 PSX.N to boost its presence in Haynesville shale.
A
I
N
R
B

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: General Insurance Corp of India Updates: Illumina, Clearlake Capital, Bain Capital Sept 3 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Tuesday: ** The Indian government has proposed to sell an up to 6.8% stake in General Insurance Corp of India (GIC) GENA.NS , an exchange filing showed.
A
I
N
R
B

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Sept 3 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Tuesday: ** California-based investment firm Clearlake Capital Group said it would buy pan-European private credit specialist MV Credit from asset manager Natixis Investment Managers. nL4N3KL0IV ** Taiwan's Shin Kong Financial 2888.TW said that it sees Taishin 2887.TW as its preferred bidder despite having received a higher $4.1 billion offer from CTBC
A
I
N
R
B

Illumina wins Grail battle in blow to EU merger power

UPDATE 2-Illumina wins Grail battle in blow to EU merger power Adds details By Foo Yun Chee BRUSSELS, Sept 3 (Reuters) - U.S. gene sequencing company Illumina ILMN.O on Tuesday won its court fight against the European Union's investigation of its $7.1 billion purchase of cancer diagnostic test maker Grail GRAL.O , a ruling set to curb Brussels' merger powers.
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.